Profile data is unavailable for this security.
About the company
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-174.92m
- Incorporated1994
- Employees198.00
- LocationOmeros Corp201 Elliott Avenue WestSEATTLE 98119United StatesUSA
- Phone+1 (206) 676-5000
- Fax+1 (206) 676-5005
- Websitehttps://www.omeros.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alimera Sciences Inc | 80.75m | -21.39m | 180.10m | 159.00 | -- | 3.90 | -- | 2.23 | -2.16 | -2.16 | 3.17 | 0.8819 | 0.8235 | 6.22 | 2.98 | 507,886.80 | -20.53 | -19.08 | -29.94 | -27.37 | 86.58 | 86.80 | -24.93 | -19.55 | 2.31 | -0.1919 | 0.5835 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
bluebird bio Inc | 21.73m | -91.17m | 181.41m | 323.00 | -- | 0.4583 | -- | 8.35 | -0.7446 | -0.7446 | 0.2139 | 2.08 | 0.0383 | -- | -- | 67,263.16 | -16.08 | -33.02 | -21.50 | -37.14 | -10.08 | 19.44 | -419.62 | -4,044.31 | 1.42 | -- | 0.00 | -- | -1.77 | -36.71 | 52.62 | -- | -26.66 | -- |
Gossamer Bio Inc | 0.00 | -179.82m | 181.82m | 135.00 | -- | 2.89 | -- | -- | -1.38 | -1.38 | 0.00 | 0.2785 | 0.00 | -- | -- | 0.00 | -61.54 | -57.43 | -74.38 | -64.38 | -- | -- | -- | -- | -- | -15.09 | 0.769 | -- | -- | -- | 21.61 | -- | -- | -- |
Kodiak Sciences Inc | 0.00 | -260.49m | 182.20m | 111.00 | -- | 0.6856 | -- | -- | -4.97 | -4.97 | 0.00 | 5.06 | 0.00 | -- | -- | 0.00 | -45.46 | -31.73 | -49.53 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
Rigel Pharmaceuticals Inc | 116.88m | -25.09m | 184.17m | 147.00 | -- | -- | -- | 1.58 | -0.1444 | -0.1444 | 0.6717 | -0.1638 | 0.9295 | 0.9713 | 3.30 | 795,115.60 | -19.95 | -28.82 | -37.72 | -47.26 | 93.92 | 97.88 | -21.47 | -35.76 | 1.76 | -4.45 | 1.93 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
Generation Bio Co | 5.90m | -126.61m | 184.81m | 174.00 | -- | 0.9061 | -- | 31.30 | -1.97 | -1.97 | 0.0916 | 3.07 | 0.0157 | -- | 2.71 | 33,931.04 | -33.72 | -36.96 | -36.60 | -39.21 | -- | -- | -2,144.51 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
Outlook Therapeutics Inc | 0.00 | -51.50m | 184.85m | 24.00 | -- | -- | -- | -- | -3.99 | -3.99 | 0.00 | -1.87 | 0.00 | -- | -- | 0.00 | -122.07 | -214.69 | -441.62 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -- | 3.00 | -- | -- | -- | 10.70 | -- | -- | -- |
Trevi Therapeutics Inc | 0.00 | -29.07m | 185.16m | 25.00 | -- | 2.22 | -- | -- | -0.2934 | -0.2934 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -27.37 | -47.39 | -30.09 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
Alpha Tau Medical Ltd | 0.00 | -29.16m | 185.32m | 121.00 | -- | 2.19 | -- | -- | -0.4203 | -0.4203 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -25.63 | -- | -26.99 | -- | -- | -- | -- | -- | -- | -- | 0.0623 | -- | -- | -- | 13.64 | -- | -- | -- |
Omeros Corp | 0.00 | -174.92m | 186.00m | 198.00 | -- | -- | -- | -- | -2.79 | -1.88 | 0.00 | -0.4087 | 0.00 | -- | -- | 0.00 | -36.09 | -55.51 | -44.88 | -70.10 | -- | -- | -- | -- | -- | -5.33 | 1.08 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
Prelude Therapeutics Inc | 0.00 | -121.83m | 188.93m | 128.00 | -- | 0.7968 | -- | -- | -2.05 | -2.05 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -48.91 | -47.21 | -53.60 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
Acumen Pharmaceuticals Inc | 0.00 | -52.37m | 189.85m | 51.00 | -- | 0.6855 | -- | -- | -1.08 | -1.08 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -20.67 | -- | -21.56 | -- | -- | -- | -- | -- | -- | -- | 0.103 | -- | -- | -- | -22.20 | -- | -- | -- |
Lifecore Biomedical Inc | 103.27m | -64.24m | 192.90m | 459.00 | -- | -- | -- | 1.87 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
Poseida Therapeutics Inc | 64.70m | -123.43m | 192.98m | 330.00 | -- | 1.84 | -- | 2.98 | -1.38 | -1.38 | 0.7175 | 1.08 | 0.2068 | -- | 7.15 | 196,069.70 | -39.45 | -40.70 | -49.32 | -47.72 | -- | -- | -190.76 | -233.49 | -- | -14.93 | 0.361 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
Holder | Shares | % Held |
---|---|---|
Ingalls & Snyder LLCas of 31 Dec 2023 | 4.55m | 7.23% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 3.94m | 6.27% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 3.09m | 4.91% |
Stifel Nicolaus & Co., Inc. (Investment Management)as of 31 Dec 2023 | 1.89m | 3.01% |
D. E. Shaw & Co. LPas of 31 Dec 2023 | 1.49m | 2.37% |
Geode Capital Management LLCas of 31 Dec 2023 | 1.34m | 2.13% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.20m | 1.91% |
Corient Private Wealth LLCas of 31 Dec 2023 | 663.66k | 1.06% |
BMO Asset Management Corp.as of 31 Dec 2023 | 563.10k | 0.90% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 559.05k | 0.89% |